Collaboration to develop a first-in-class α9/α10 nicotinic acetylcholine receptor antagonist for the treatment of chronic pain Kineta to receive undisclosed

Kineta Immuno-oncology Unveils New Data Demonstrating Tumor Immunity in Multiple Tumor Models Small molecule RIG-I agonist induces innate immune responses,

Kineta Immuno-oncology to Present at Keystone Symposia on Molecular and Cellular Biology: Cancer Immunotherapy Combinations Conference New data on Kineta’s

Kineta Immuno-oncology Announces Presentation on Novel RIG-I Agonists at Immuno-Oncology Frontiers World Conference SEATTLE, WA, January 22, 2018 – Kineta